Composition for wound healing or skin regeneration comprising multi-copper oxidase peptide and peptide derived therefrom

Multi-copper oxidase peptides with specific amino acid sequences address copper-induced skin damage and impaired wound healing by binding copper, effectively restoring normal wound healing and skin regeneration.

WO2024237752A1PCT designated stage expired Publication Date: 2024-11-21NAT MARINE BIODIVERSITY INST OF KOREA
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/095567
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-03-15
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Excessive copper exposure leads to skin damage, impaired wound healing, and toxicity issues, including cancer promotion and neurological disorders, with existing treatments lacking effective solutions for copper-induced damage.

Method used

Development of multi-copper oxidase peptides and their derivatives, specifically peptides with amino acid sequences SEQ ID NOs: 1 to 7, which exhibit high binding affinity to copper, restoring normal wound healing and skin regeneration by inhibiting copper toxicity.

Benefits of technology

The peptides effectively bind copper, restoring wound healing and skin regeneration capabilities inhibited by excessive copper exposure, demonstrating high binding capacity and physiological activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024095567_21112024_PF_FP_ABST
    Figure KR2024095567_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to use of a multi-copper oxidase peptide and a peptide derived therefrom for wound treatment or skin regeneration. It was confirmed that the multi-copper oxidase peptide and peptide derived therefrom according to the present invention not only had excellent binding affinity to copper, but also restored wound healing recovery inhibited by excessive copper exposure to a normal level. Therefore, the peptide of the present invention can have various applications in fields related to the suppression of skin damage caused by heavy metals and wound healing.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for wound healing or skin regeneration comprising a multi-copper oxidase peptide and a peptide derived therefrom

[0001] The present invention relates to the use of multi-copper oxidase peptides and peptides derived therefrom for wound treatment or skin regeneration.

[0002] Ceruloplasmin is the primary protein that transports copper in the blood and plays a crucial role in iron metabolism. Ceruloplasmin contains six copper atoms in its protein structure and is known to be synthesized in the liver.

[0003] Meanwhile, copper is an essential catalytic and structural cofactor in many enzymes and is involved in key biological processes. As an essential trace nutrient, copper is balanced within the body through the homeostasis of internalization and excretion. Excessive copper in fish can damage the gills, liver, intestines, and nervous system. In humans, excessive copper is a tumorigenic agent, stimulating cancer cell proliferation and inducing behavioral changes. Furthermore, excessive copper in humans is known to cause Alzheimer's disease and has also been linked to Wilson's disease, autism spectrum disorders, and acute leukemia. As mentioned above, excessive copper in the body is toxic, but the molecular mechanisms underlying this toxicity remain unknown.

[0004] Accordingly, the inventors of the present invention completed the present invention by confirming the skin wound healing and regeneration effects of a multi-copper oxidase peptide and a peptide derived therefrom.

[0005] Accordingly, the purpose of the present invention is to provide a wound treatment composition comprising a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

[0006] Another object of the present invention is to provide a composition for skin regeneration comprising a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

[0007] Another object of the present invention is to provide a cosmetic composition for removing heavy metals from the skin, comprising a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

[0008] Another object of the present invention is to provide a wound treatment method comprising the step of treating a subject with a peptide comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7.

[0009] Another object of the present invention is to provide a use of a peptide comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7 for the manufacture of a wound healing agent.

[0010] To achieve the above purpose, the present invention provides a pharmaceutical composition for wound treatment comprising a peptide comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7.

[0011] In addition, the present invention provides a pharmaceutical composition for wound treatment, comprising a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

[0012] In addition, the present invention provides a cosmetic composition for skin regeneration comprising a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

[0013] In addition, the present invention provides a food composition for skin regeneration comprising a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

[0014] In addition, the present invention provides a cosmetic composition for removing heavy metals from the skin, comprising a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

[0015] The present invention also provides a wound treatment method comprising the step of treating a subject with a peptide comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7.

[0016] The present invention also provides the use of a peptide comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7 for the manufacture of a wound healing agent.

[0017] The multi-copper oxidase peptide according to the present invention and peptides derived therefrom not only exhibit excellent copper binding affinity, but also restore wound healing impaired by excessive copper exposure to normal levels. Therefore, the peptide of the present invention can be utilized in various fields related to the inhibition of skin damage caused by heavy metals and wound healing.

[0018] Figure 1 is a diagram showing the results of measuring the concentration of copper ions after analyzing the copper binding affinity of a multi-copper oxidase peptide according to the present invention and a peptide derived therefrom.

[0019] Figure 2 is a diagram showing the results of calculating the copper binding rate of a multi-copper oxidase peptide according to the present invention and a peptide derived therefrom.

[0020] Figure 3 is a diagram showing the results of measuring the binding energy of the multi-copper oxidase peptide Om_CP001 according to the present invention to copper.

[0021] Figure 4 is a diagram showing the results of measuring the binding energy of the multi-copper oxidase peptide Om_CP002 according to the present invention to copper.

[0022] Figure 5 is a diagram showing the results of measuring the binding energy of the active domain Om_CP002s derived from the multi-copper oxidase peptide Om_CP002 according to the present invention to copper.

[0023] Figure 6 is a diagram showing the results of measuring the binding energy of the improved peptide Om_CP002s1 of the active domain Om_CP002s derived from the multi-copper oxidase peptide Om_CP002 according to the present invention to copper.

[0024] Figure 7 is a diagram showing the results of measuring the binding energy of the improved peptide Om_CP002s2 of the active domain Om_CP002s derived from the multi-copper oxidase peptide Om_CP002 according to the present invention to copper.

[0025] Figure 8 is a diagram showing the results of measuring the binding energy of the improved peptide Om_CP002s3 of the active domain Om_CP002s derived from the multi-copper oxidase peptide Om_CP002 according to the present invention to copper.

[0026] Figure 9 is a diagram showing the results of measuring the binding energy of the improved peptide Om_CP002s4 of the active domain Om_CP002s derived from the multi-copper oxidase peptide Om_CP002 according to the present invention to copper.

[0027] Figure 10 is a diagram showing the results of a cytotoxicity analysis of peptides Om_CP002 and Om_CP002s according to the present invention against an epidermal cell line.

[0028] Figure 11 is a diagram showing the results of observing colony formation of peptides Om_CP002 and Om_CP002s according to the present invention using an inverted microscope.

[0029] Figure 12 is a diagram showing the results of calculating the colony forming ability of peptides Om_CP002 and Om_CP002s according to the present invention.

[0030] Figure 13 is a diagram showing the results of confirming the wound healing recovery rate of peptides Om_CP002 and Om_CP002s according to the present invention in HaCaT cells.

[0031] Figure 14 is a graph analyzing the wound healing recovery rate results of Figure 13.

[0032] Figure 15 is a diagram showing the results of confirming the wound healing recovery rate of peptides Om_CP002 and Om_CP002s according to the present invention in HDF cells.

[0033] Figure 16 is a graph analyzing the wound healing recovery rate results of Figure 14.

[0034] Figure 17 is a diagram showing the results of observing wound healing recovery of peptides Om_CP002, Om_CP002s, Om_CP002s1, Om_CP002s2, Om_CP002s3, and Om_CP002s4 according to the present invention using an inverted microscope.

[0035] Figure 18 is a diagram showing the results of calculating the wound healing recovery rate of peptides Om_CP002, Om_CP002s, Om_CP002s1, Om_CP002s2, Om_CP002s3, and Om_CP002s4 according to the present invention.

[0036] Hereinafter, the present invention will be described in detail.

[0037] According to an aspect of the present invention, the present invention provides a wound treatment composition comprising a peptide represented by a peptide comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7. Specifically, the wound treatment composition may be a pharmaceutical composition or a quasi-drug composition.

[0038] In the present invention, a peptide refers to a linear molecule formed by amino acid residues linked together by peptide bonds. The peptide may be manufactured using chemical synthesis methods known in the art, preferably using solid-phase synthesis techniques, but is not limited thereto.

[0039] The scope of the present invention includes functional equivalents of peptides comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7.

[0040] The above "functional equivalent" refers to a peptide having at least 80%, preferably 90%, and more preferably 95% sequence homology (i.e., identity) with the peptide according to the present invention as a result of addition, substitution, or deletion of amino acids, for example, including 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and 100% sequence homology, and exhibiting substantially the same physiological activity as the peptide according to the present invention. In this specification, sequence homology and identity are defined as the percentage of amino acid residues of a candidate sequence relative to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7, after aligning the candidate sequence with an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7 and introducing gaps. Where necessary, conservative substitutions are not considered as part of sequence identity in order to obtain the maximum percentage sequence identity. N-terminal, C-terminal, or internal extensions, deletions, or insertions of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7 are not construed as sequences affecting sequence identity or homology.

[0041] Additionally, the sequence identity can be determined by commonly used standard methods for comparing similar portions of the amino acid sequences of two polypeptides. Computer programs such as BLAST or FASTA align two polypeptides so that each amino acid matches optimally (along the full-length sequence of one or both sequences or along a predicted portion of one or both sequences). The programs provide a default opening penalty and a default gap penalty, and provide a scoring matrix such as PAM250 (a standard scoring matrix) that can be used in conjunction with the computer program. For example, the percent identity can be calculated as follows: the total number of identical matches is multiplied by 100, and then divided by the sum of the length of the longer sequence within the matched span and the number of gaps introduced into the longer sequence to align the two sequences.

[0042] The term “substantially homogeneous physiological activity” as used above refers to high binding affinity for heavy metals, inhibition of skin damage caused by heavy metals, and wound healing activity.

[0043] In the present invention, "heavy metal" refers to a metal with a specific gravity of approximately 4.0 to 5.0. Among heavy metals, some are harmful to the human body and their concentration in food, beverages, and the atmosphere is regulated. Examples of heavy metals include mercury, copper, zinc, cadmium, and chromium.

[0044] In a specific embodiment of the present invention, the wound may be a wound in which wound healing recovery is reduced due to heavy metal exposure. In an embodiment of the present invention, it was confirmed that wound healing recovery is reduced due to heavy metal exposure, and this phenomenon was confirmed to be restored to normal levels following peptide treatment of the present invention.

[0045] In a specific embodiment of the present invention, the peptide is preferably capable of restoring colony-forming ability reduced by excessive exposure to heavy metals. In an embodiment of the present invention, it was confirmed that colony-forming ability was reduced by heavy metal exposure, and this phenomenon was confirmed to be restored to normal levels by treatment with the peptide of the present invention.

[0046] In a specific embodiment of the present invention, it is preferred that the peptide binds to a copper ion.

[0047] In a specific embodiment of the present invention, the concentration of the peptide is preferably 0.1 to 100 μM, more preferably 1 to 90 μM, even more preferably 10 to 80 μM, still more preferably 20 to 70 μM, and most preferably 50 μM.

[0048] In the present invention, “wound treatment” means all actions that regenerate skin damaged by a wound, etc., by increasing colony formation ability and promoting skin cell migration ability.

[0049] When the composition of the present invention is used as a pharmaceutical composition, the pharmaceutical composition of the present invention can be formulated and used in various forms according to conventional methods. For example, it can be formulated in oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, and can be formulated and used in the form of topical preparations, suppositories, and sterile injectable solutions.

[0050] The composition of the present invention may contain one or more known effective ingredients having a preventive or therapeutic effect on wound healing together with the peptide according to the present invention.

[0051] The composition of the present invention may further include a pharmaceutically acceptable additive. At this time, the pharmaceutically acceptable additive may be starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, taffy, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, etc. The pharmaceutically acceptable additive according to the present invention is preferably included in the composition in an amount of 0.1 to 90 parts by weight, but is not limited thereto.

[0052] The composition of the present invention can be administered in various oral or parenteral dosage forms during actual clinical administration. When formulating, it can be prepared using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants that are commonly used. It is preferable to use suitable formulations known in the art as disclosed in the literature (Remington's Pharmaceutical Science, recently, Mack Publishing Company, Easton PA).

[0053] The above solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. In addition, the above liquid preparations for oral administration include suspensions, oral solutions, emulsions, syrups, etc., and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. may be included.

[0054] The above-mentioned parenteral administration preparations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may include witepsol, macrogol, Tween 61, cacao butter, laurin, and glycerogelatin.

[0055] The dosage of the pharmaceutical composition of the present invention may vary depending on the method of formulating the pharmaceutical composition, the method of administration, the time of administration, and / or the route of administration, and may vary depending on various factors including the type and degree of the response to be achieved by administration of the pharmaceutical composition, the type, age, weight, general health condition, symptoms or degree of the disease, sex, diet, excretion, drugs used simultaneously or simultaneously in the subject, other components of the composition, and similar factors well known in the medical field, and a person having ordinary knowledge in the relevant technical field can easily determine and prescribe an effective dosage for the desired treatment.

[0056] The dosage of the pharmaceutical composition of the present invention is preferably administered at a concentration of, for example, 0.05 to 5 mg / kg, more preferably 0.1 to 0.4 mg / kg, even more preferably 0.2 to 0.35 mg / kg, and even more preferably 0.25 mg / kg, but the dosage does not limit the scope of the present invention in any way.

[0057] The route and method of administration of the pharmaceutical composition of the present invention may be independent of each other, and are not particularly limited in their method, and any route and method of administration may be followed as long as the pharmaceutical composition can reach the target area.

[0058] The pharmaceutical composition may be administered orally or parenterally. Parenteral administration methods include, for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration, or subcutaneous administration.

[0059] The pharmaceutical composition of the present invention can be used alone for wound treatment or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.

[0060] In the present invention, the above-mentioned pharmaceutical composition is a pharmaceutical composition for the purpose of treating wounds.

[0061] In the present invention, quasi-drugs refer to products that are used for the purpose of diagnosing, treating, improving, alleviating, managing or preventing diseases of humans or animals, and have a milder effect than pharmaceutical products. For example, according to the Pharmaceutical Affairs Act, quasi-drugs are products other than those used for pharmaceutical purposes, and include textile products used for the treatment or prevention of diseases of humans and animals, rubber products, things that have a mild or no direct effect on the human body, are not instruments or machines and similar things, and disinfectants and insecticides for preventing infectious diseases.

[0062] The type or formulation of the pharmaceutical composition of the present invention is not particularly limited, but may preferably be a disinfectant, a shower foam, a gargle, a wet tissue, a detergent soap, a hand wash, a humidifier filler, a mask, an ointment, or a filter filler.

[0063] When the peptide according to the present invention is included in a quasi-drug, the peptide may be used as is or in combination with other quasi-drug ingredients, and may be used appropriately according to a conventional method. The amount of active ingredients mixed may be appropriately determined depending on the intended use, and the quasi-drug composition according to the present invention may contain the peptide according to the present invention in an amount of 0.01 to 20 wt% based on the total weight of the composition.

[0064] According to another aspect of the present invention, the present invention provides a composition for skin regeneration comprising a peptide represented by an amino acid sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 1 to 7. Specifically, the composition for skin regeneration may be a cosmetic composition or a food composition.

[0065] When the skin regeneration composition according to the present invention is a cosmetic composition, the cosmetic composition of the present invention may further include conventional auxiliary ingredients and carriers such as antioxidants, stabilizers, solubilizers, vitamins, pigments, fragrances, etc., which are commonly used in cosmetic compositions, in addition to the above-mentioned effective ingredients. For example, the cosmetic composition may further include auxiliary ingredients such as glycerin, butylene glycol, polyoxyethylene hydrogenated castor oil, tocopheryl acetate, citric acid, panthenol, squalane, sodium citrate, and allantoin.

[0066] Since the cosmetic composition of the present invention is basically applied to the skin, it can be manufactured into any formulation that is commonly manufactured with reference to cosmetic compositions in the art. For example, it can be formulated into a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, and spray, but is not limited thereto. More specifically, it can be manufactured into the formulation of a flexible toner, a nourishing toner, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, cleansing water, a mask pack, a spray, or a powder.

[0067] When the formulation of the present invention is a paste, cream or gel, the carrier component may include animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc.

[0068] When the formulation of the present invention is a powder or spray, the carrier component may include lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc., and in particular, when it is a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, dimethyl ether, etc.

[0069] When the formulation of the present invention is a solution or emulsion, the carrier component may include a solvent, a solubilizer, an emulsifier, etc., and specifically, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid ester of sorbitan, etc.

[0070] When the formulation of the present invention is a suspension, the carrier component may include a liquid diluent such as water, ethanol, or propylene glycol; a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, or polyoxyethylene sorbitan ester; microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tragacanth.

[0071] When the formulation of the present invention is a surfactant-containing cleansing agent, the carrier component may include fatty alcohol sulfate, fatty alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, ethoxylated glycerol fatty acid ester, etc.

[0072] The food composition for skin regeneration according to the present invention can be used as a health functional food, food additive or dietary supplement.

[0073] When the peptide according to the present invention is used as a food additive, it can be used appropriately according to a conventional method, such as adding the mixture as is or mixing it with other foods or food ingredients.

[0074] In addition, the amount of the peptide according to the present invention may be suitably changed depending on the purpose of use (prevention, health, or therapeutic treatment), and is preferably included in an amount of 0.01 to 95 wt%, and more preferably 1 to 80 wt%, based on the total weight of the food composition. If the content is less than 0.01 wt%, the antioxidant or anti-inflammatory effect may be minimal, and if it exceeds 95 wt%, the effect increase rate compared to the amount used may be low, making it uneconomical.

[0075] As a specific example, when manufacturing food or beverages, the peptide according to the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, relative to the raw material. However, when consumed for long-term health and hygiene purposes or for health management, the peptide may be added in an amount below the above range. Since there are no safety issues, the active ingredient may also be used in an amount exceeding the above range.

[0076] There is no particular limitation on the type of the above food, but examples of foods to which the peptide according to the present invention can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, etc., and include all health foods in the conventional sense.

[0077] When the food composition of the present invention is manufactured into a beverage, it may contain various flavoring agents or additional ingredients such as natural carbohydrates, as in conventional beverages. The natural carbohydrates may include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; natural sweeteners such as dextrin and cyclodextrin; and synthetic sweeteners such as saccharin and aspartame. The natural carbohydrates are contained in an amount of 0.01 to 10 wt%, preferably 0.01 to 0.1 wt%, based on the total weight of the food composition of the present invention.

[0078] The food composition of the present invention may include various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc., and may include fruit pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages, but is not limited thereto. These components may be used independently or in combination. The proportion of the above additives is not particularly limited, but is preferably included within the range of 0.01 to 0.1 wt% with respect to the total weight of the food composition of the present invention.

[0079] In the case of long-term consumption for the purpose of health and hygiene or health control, the food composition of the present invention can be taken for a long period of time because there is no problem in terms of safety.

[0080] According to another aspect of the present invention, the present invention provides a cosmetic composition for removing heavy metals from the skin, comprising a peptide represented by an amino acid sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 1 to 7.

[0081] In a specific embodiment of the present invention, the peptide preferably reduces or eliminates skin penetration of heavy metals. More specifically, the peptide is characterized by binding to heavy metals, such as copper, with high binding affinity, thereby preventing copper from penetrating into skin cells, thereby reducing or eliminating skin penetration of heavy metals.

[0082] In a preferred embodiment of the present invention, the heavy metal may be derived from fine dust or yellow dust. Specifically, the heavy metal may penetrate the skin by contacting it through the atmospheric environment, and may be derived from fine dust or yellow dust. Therefore, heavy metals contained in fine dust or yellow dust can be blocked or eliminated from penetrating the skin by contacting it.

[0083] In the present invention, it was experimentally confirmed that the peptide according to the present invention has excellent binding affinity to heavy metals. Furthermore, when cells are exposed to heavy metals, colony formation and wound healing activity are inhibited. However, this phenomenon was confirmed to be restored to normal levels by treatment with the peptide according to the present invention. These results indicate that the peptide according to the present invention binds to and removes heavy metals, thereby restoring colony formation and wound healing activity. Therefore, the peptide according to the present invention can be usefully utilized for removing heavy metals from the skin.

[0084] Also provided is a method for treating a wound, comprising the step of treating a subject with a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

[0085] The present invention also provides the use of a peptide comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7 for the manufacture of a wound healing agent.

[0086] Duplicate contents are omitted in consideration of the complexity of this specification, and terms not otherwise defined in this specification have meanings commonly used in the technical field to which the present invention belongs.

[0087] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.

[0088] Example 1. Screening of multi-copper oxidase peptides and their active domains.

[0089] In this example, a multi-copper oxidase peptide was obtained from octopus ceruloplasmin, and the active domain of the multi-copper oxidase peptide and an improved peptide thereof were designed.

[0090] Specifically, the full-length octopus ceruloplasmin gene information (SEQ ID NO: 8) isolated from the cDNA library by octopus tissue and developmental stage was used to obtain protein information using a protein conversion program (ExPASy-translate tool, https: / web.expasy.org / translate / ). The obtained full-length ceruloplasmin protein information (SEQ ID NO: 9) was analyzed using the active domain search site [ExPASy prosite (https: / prosite.expasy.org / ), MOTIF Search (https: / www.genome.jp / tools / motif / )]. As a result, the multicopper oxidase 1 domain was identified as amino acids 324-344 (21 residues) and amino acids 1019-1039 (21 residues). To identify the optimal size and activity information for each of the two 21-amino acid poly-copper oxidase peptides obtained, protein information was analyzed using the active domain search site [ExPASy prosite (https: / prosite.expasy.org / ), MOTIF Search (https: / www.genome.jp / tools / motif / )]. The obtained poly-copper oxidase peptides were named Om_CP001 (SEQ ID NO: 1) and Om_ Om_CP002 (SEQ ID NO: 2), respectively.

[0091] The optimal peptide size and activity information of the above Om_CP001 (SEQ ID NO: 1) and Om_ Om_CP002 (SEQ ID NO: 2) were further analyzed. The analysis utilized the active domain search site [ExPASy prosite (https: / prosite.expasy.org / ), MOTIF Search (https: / www.genome.jp / tools / motif / )]. As a result, based on the activity prediction results using the optimal peptide size and activity information analysis program (ExPASy prosite), 12 amino acids (positions 1024-1035 of SEQ ID NO: 2) derived from Om_CP002, a multi-copper oxidase peptide, were synthesized by requesting a peptide synthesis company. The above 12 peptides derived from Om_CP002 (i.e., multicopper oxidase peptide active domains) were named Om_CP002s and are represented by the amino acid sequence of SEQ ID NO: 3.

[0092] An improved peptide of the above Om_CP002s (SEQ ID NO: 3) was designed, and information on the designed improved peptide is as follows.

[0093] - Om_CP002s1 (SEQ ID NO: 4): An improved peptide in which the second cysteine ​​of Om_CP002s (SEQ ID NO: 3) is replaced with histidine.

[0094] - Om_CP002s2 (SEQ ID NO: 5): An improved peptide in which the second cysteine ​​of Om_CP002s (SEQ ID NO: 3) is substituted with histidine and the 10th or 11th glycine is deleted.

[0095] - Om_CP002s3 (SEQ ID NO: 6): An improved peptide in which the second cysteine ​​of Om_CP002s (SEQ ID NO: 3) is replaced with histidine and both the 10th and 11th glycines are deleted.

[0096] - Om_CP002s4 (SEQ ID NO: 7): An improved peptide in which the second cysteine ​​of Om_CP002s (SEQ ID NO: 3) is replaced with histidine, the 10th and 11th glycines are both deleted, and the 12th methionine is deleted.

[0097] To increase the stability of existing and designed improved peptides, C-term amidation was added to synthesize peptides with a purity of 95% or higher.

[0098] Specific information on the aforementioned peptides is shown in Table 1.

[0099]

[0100] The positive control group in the experiments described below used hexa-histidine, which consists of six histidines that bind to copper.

[0101] Example 2. Copper binding strength analysis

[0102] For copper binding analysis, CuSO4 (50 uM, 25 uM, 12.5 uM) was sequentially set as a control group, and samples were prepared with 50 uM CuSO4 and the peptides (25 uM, 50 uM) of Table 1 in a 1:1 concentration ratio. The binding of copper ions and peptides in the prepared samples was analyzed using a copper assay kit (MAK127, Sigma). Specifically, the provided colorimetric reagent was added to the PBS solvent containing CuSO4 / chelator to induce the reaction. After incubation for 5 minutes, the absorbance was measured at 359 nm using a spectrophotometer. The standard curve was confirmed (R2 = 0.99) with the absorbance values ​​of 100 ug / dL, 200 ug / dL, and 300 ug / dL copper standard reagents. The concentration of copper was calculated using the following mathematical formula 1, and the conversion factor (Cu 100 ug / dL = 15.5 uM) was used to calculate the value.

[0103] [Mathematical Formula 1]

[0104] Concentration of copper (ug / dL(Cu2+)) = (Asample - Ablank) / (Astandard-Ablank) x 300

[0105] As a positive control in this experiment, hexa-histidine was treated under the same conditions as the peptide. The results of analyzing the binding affinity of copper ions and the peptide and measuring the concentration of copper ions are shown in Figure 1, and the copper binding rate calculated based on this is shown in Figure 2.

[0106] As shown in Figures 1 and 2, it was confirmed that the peptides Om_CP002s (77%), Om_CP002s1 (68.4%), Om_CP002s3 (67.8%), Om_CP002s4 (65.6%), Om_CP002s2 (59.4%), Om_CP001 (28%), and Om_CP002 (26.4%) in Table 1 had different copper binding affinities.

[0107] Example 3. Measurement of binding energy for copper ions

[0108] The binding energies of the seven peptides in Table 1 to copper (CuSO4) were determined. Specifically, the concentration of each peptide was 50 μM, and the copper (CuSO4) concentration was 1 mM. The binding energies of the seven peptides in Table 1 to copper were measured using an Auto-iTC200 device, and the results are shown in Figures 3 to 9, respectively.

[0109] As shown in Figures 3 to 9, the seven peptides in Table 1 were confirmed to have very fast binding rates to copper ions. In addition, the seven peptides were confirmed to have similar numbers of molecules binding to copper ions.

[0110] Example 4. Cytotoxicity analysis on epidermal cell lines

[0111] Epidermal cell line (HaCaT) cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic 100X at 37℃ in a humidified incubator with 5% CO2. For cell growth rate (CCK-8 assay), each cell line was seeded into a 96-well plate at a density of 5 × 103 cells per well and cultured for 24 hours in a 5% CO2 incubator at 37℃. Om_CP002 or Om_CP002s peptide (10 uM) was treated in the CuSO4 treatment group (100 uM, 50 uM, 25 uM) and cultured for 24 hours. Cultured cells were incubated in fresh medium containing 10 μl of CCK-8 solution for 3 hours, and then absorbance was measured at 450 nm using a spectrophotometer (Molecular devices, spectramax i3x). The percentage of viable cells was calculated based on the measured value, and all results were repeated three times. The results of cytotoxicity testing are shown in Figure 10.

[0112] As shown in Fig. 10, the epidermal cell line (HaCaT) showed that cell growth was inhibited by 19.5% (100 uM), 42.5% (50 uM), and 72.3% (25 uM) according to CuSO4 treatment, respectively. The Om_CP002 treatment group showed that cell growth was recovered by 27.3% (CuSO4 100 uM), 52.9% (CuSO4 50 uM), and 86.2% (CuSO4 25 uM), respectively. In addition, the Om_CP002s treatment group showed that cell growth was recovered by 30.7% (CuSO4 100 uM), 58.0% (CuSO4 50 uM), and 99.2% (CuSO4 25 uM). Meanwhile, in the control condition without copper exposure, the cell proliferation and inhibitory effects by Om_CP002 and Om_CP002s peptides were not confirmed.

[0113] Example 5. Colony formation assay

[0114] To compare the growth of cell lines induced by peptides, a colony formation assay was performed. Each cell line was seeded into 30 mm petri dishes at 1 × 103 cells per well. The seeded cells were cultured for 24 hours in a 5% CO2 incubator at 37°C. The cultured cells were treated with CuSO4 (50 μM), and the peptides Om_CP002 and Om_CP002s were added to a concentration of 10 μM each. After culturing the cells with the peptides for 7 days, the culture medium was removed and stained with 0.5% crystal violet reagent for 10 minutes. The stained cells were washed with PBS solution, and the formed colonies were observed under a microscope. The results of the microscopic observation are shown in Figure 11, and the colony formation ability was calculated based on the results are shown in Figure 12.

[0115] As shown in Figures 11 and 12, the CuSO4 treatment group showed a colony-forming ability of 45.9%. On the other hand, the peptide Om_CP002 and Om_CP002s treatment groups showed colony-forming abilities of 64% and 79%, respectively. The above results indicate that the copper-induced cell growth inhibition in skin cells is restored by the peptides Om_CP002 and Om_CP002s.

[0116] Example 6. Wound healing effect by peptide under copper overexposure conditions in skin (HaCaT, HDF) cells.

[0117] 2x105 cells (HaCaT, HDF) were cultured in 12-well plates for 24 hours to induce the formation of cell monolayers, and scratch damage was induced using a pipette tip. The experimental groups were divided into a control group (DMSO), a CuSO4 treatment group (50 μM CuSO4), a peptide treatment group (50 μM CuSO4 and 20 μM peptide), and a positive control group (20 μM hexa-histidine), and CuSO4 and peptide (Om_CP002 or Om_CP002s) were treated according to each condition. The extent of scratch damage recovery was observed using an inverted microscope at 0, 24, and 48 hours after CuSO4 and peptide treatment. In addition, the area was measured and analyzed for the degree of cell migration change using Image J. The results confirming the wound healing effect in HaCaT and HDF cells are shown in Figures 13 to 16, respectively.

[0118] As shown in Figures 13 and 14, CuSO4-treated HaCaT cells showed a wound healing recovery rate of approximately 41% compared to the control group (100%). The CuSO4 and peptide (Om_CP002 or Om_CP002s)-treated groups showed significantly increased wound healing recovery rates of 70% and 93%, respectively.

[0119] As shown in Figures 15 and 16, CuSO4-treated HDF cells showed a wound healing recovery rate of approximately 19% compared to the control group (100%). The CuSO4 and peptide (Om_CP002 or Om_CP002s)-treated groups showed significantly increased wound healing recovery rates of 74.5% and 89.5%, respectively.

[0120] Additionally, the wound healing effects of peptides Om_CP002, Om_CP002s, Om_CP002s1, Om_CP002s2, Om_CP002s3, and Om_CP002s4 in HDF cells were further analyzed. HDF cells were prepared in the same manner as in the previous experiment, and CuSO4 (50 μM) and each peptide (10 μM) were treated according to the experimental conditions. The results of observing the cells using an inverted microscope are shown in Figure 6A, and the results of calculating the wound healing recovery rate are shown in Figure 6B.

[0121] As shown in Figures 17 and 18, HDF cells treated with CuSO4 showed a wound healing recovery rate of 42% at 24 hours and 73% at 48 hours. HDF cells treated with CuSO4 and peptides showed a wound healing recovery rate that recovered to the level of the normal group over time.

[0122] The above results indicate that copper overload inhibits wound healing under scratch injury experimental conditions, which is restored to the normal group level by treatment with the peptide of the present invention.

[0123] In summary, the present inventors developed improved peptides (Om_CP002s1, Om_CP002s2, Om_CP002s3, and Om_CP002s4) of the multi-copper oxidase activity domain (Om_CP002s). Furthermore, the improved peptides not only exhibited excellent copper binding affinity, but also restored wound healing recovery rates inhibited by excessive copper exposure to normal levels. Therefore, the peptides of the present invention can be utilized in various fields related to the inhibition of heavy metal-induced skin damage and wound healing.

[0124] While specific aspects of the present invention have been described in detail, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A pharmaceutical composition for wound treatment, comprising a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

2. A composition according to claim 1, wherein the wound is a wound in which wound healing recovery is inhibited by exposure to heavy metals.

3. A composition according to claim 1, wherein the peptide restores colony forming ability reduced by excessive exposure to heavy metals.

4. A composition according to claim 1, wherein the peptide binds to a copper ion.

5. A composition according to claim 1, wherein the peptide has a concentration of 0.1 to 100 μM.

6. A pharmaceutical composition for wound treatment, comprising a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

7. A cosmetic composition for skin regeneration, comprising a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

8. A cosmetic composition for skin regeneration, wherein the peptide in paragraph 7 reduces or eliminates skin penetration of heavy metals.

9. A cosmetic composition for skin regeneration in paragraph 8, wherein the heavy metal is derived from fine dust or yellow dust.

10. A food composition for skin regeneration, comprising a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

11. A wound treatment method comprising a step of treating an object with a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7.

12. Use of a peptide comprising any one amino acid sequence selected from the group consisting of sequence numbers 1 to 7 for the manufacture of a wound healing agent.

Citation Information

Patent Citations

  • Recombinant polypeptide for use in promoting scarless wound healing and adhesive biomaterial comprising thereof

    KR101807593B1

  • Jig device for wire harness

    KR1020210087607A

  • Server, payment gateway server and operating method of server

    KR1020230009571A

  • Method for Predicting Soybean Yield in North-America According to Weather

    KR102253347B1

  • Composition for preventing or treating neurological disorders related to copper metabolism comprising multicopper oxidase peptide

    KR102265501B1